ARA290
ARA-290 (Cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without erythropoietic effects. Tissue repair has been reported in animal injury models, and it is described as having neuroprotective properties.
8 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
ARA-290 (Cibinetide) is an investigational compound tested in mid-stage (phase 2) human trials. ARA-290 (Cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor (IRR) without erythropoietic effects.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Subcutaneous injection, Intravenous |
| Research stage | Phase 2 |
| Dosing | Published research: 1, 4 or 8 mg/day subcutaneous for 28 days in humans with sarcoidosis small-fiber neuropathy (phase 2b, n=64) details1, 4 or 8 mg/day s.c. for 28 days in humans with sarcoidosis small-fiber neuropathy (phase 2b, n=64); 4 mg/day s.c. self-administered for 28 days in type 2 diabetes (phase 2)Community-reportedCommunity-reported: 2–4 mg, subcutaneous injection, Intravenous |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a small piece designed from the hormone EPO that is thought to switch on the body's tissue-protection signals without making more red blood cells. Proposed mechanism: a non-erythropoietic peptide designed from erythropoietin that interacts selectively with the innate repair receptor, which mediates tissue protection (Brines 2015). That receptor is described as a heterodimer of the EPO receptor and CD131/βc receptor whose activation triggers anti-inflammatory and tissue-protective signalling (JAK2/STAT5, PI3K/Akt, NF-κB suppression) without stimulating red blood cell production.
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedSome users report running ARA-290 (Cibinetide) at 2–4 mg (subcutaneous injection, intravenous). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
ARA-290, also known as Cibinetide, is a novel peptide that represents a breakthrough in separating the tissue-protective properties of erythropoietin from its blood cell-stimulating effects. Developed by Araim Pharmaceuticals, the peptide is an 11-amino acid linear sequence derived from the helix B surface of EPO. It selectively activates the innate repair receptor (IRR) — a heterodimer of the EPO receptor and the beta common receptor (CD131) — which is expressed on damaged or stressed tissues. This selectivity is intended to separate tissue-protective signaling from EPO's erythropoietic effects; tissue repair and reduced inflammation have been reported in animal injury models. Phase 2 clinical trials have been completed in sarcoidosis-associated small nerve fiber loss (a phase 2b RCT, n=64, reported improved corneal nerve fiber area at 4 mg) and in type 2 diabetes (improved neuropathic symptoms over 28 days).
Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11 amino acids)
Molecular Weight: 1,257.4 Da
Molecular Formula: C50H88N16O22
Structure Details: Linear undecapeptide derived from the helix B surface of erythropoietin (EPO). Designed to mimic the EPO-IRR binding domain without activating the classical homodimeric EPO receptor responsible for erythropoiesis.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| ARA-290 (Cibinetide) | No published PK data found | Subcutaneous injection, Intravenous | Phase 2 |
| BPC-157 | Elimination t1/2 < 30 min (rats and beagle dogs, IV and IM); IM bioavailability ~14-19% rats, 45-51% dogs | Subcutaneous injection | Preclinical (animal) |
| Copper Peptide AHK-Cu | Topical (not systemically relevant) | Topical | In vitro only |
| GHK-Cu | No published PK data found | Subcutaneous or topical | Cosmetic/topical |
| Pentapeptide-18 | Unknown | Topical | Cosmetic/topical |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Healing category. View All Healing Peptides
Immune, Research
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.